A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
REGULATORY
Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
The Japanese government on June 17 officially decided to set up a new agency to orchestrate the country’s pandemic responses under the Cabinet Secretariat in a bid to bolster its command tower functions in the event of emergencies. The decision…
To read the full story
Related Article
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- Deliberations Underway for Transfer of Some MHLW Functions to Boost Pandemic Responses: Vice Health Minister
August 10, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
REGULATORY
- Optimal Use Guidelines Issued for Vyepti; Updates for Leqembi, Kisunla, Keytruda
November 13, 2026
- New Radiopharma Action Plan Urges Domestic CDMO Development: Draft
November 13, 2026
- Chuikyo OKs Tougher CEA Price Cuts for Drugs Tagged “Cost Increase”
November 12, 2026
- Chuikyo Weighs “Agile Response” to MFN as Providers Question Drug Lag, Loss Impact
November 12, 2026
- Japan to List Eylea Biosimilars from SamChunDang, Celltrion on Nov. 13
November 12, 2026
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…